Purple Biotech 5/21/2024 Earnings Report

Purple Biotech EPS Results

• Actual EPS: -$3.20
• Consensus EPS: -$3.00
• Beat/Miss: Missed by -$0.20
• One Year Ago EPS: N/A

Purple Biotech Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Purple Biotech Announcement Details

• Date: 5/21/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Purple Biotech (NASDAQ:PPBT), Inc. (NASDAQ:PPBT) is a biotechnology company dedicated to the discovery and development of novel therapeutics for rare and underserved diseases. The company operates a proprietary discovery platform that integrates multi-omics data, advanced bioinformatics and machine learning to uncover and validate new drug targets. Through its in-house capabilities, Purple Biotech advances small-molecule and biologic candidates from early target identification through lead optimization, aiming to streamline the preclinical development process and reduce time to clinic.

At the core of Purple Biotech’s pipeline are programs targeting genetic, metabolic and neurodegenerative disorders. The company’s lead programs include a small-molecule modulator for a rare lysosomal storage disease and a monoclonal antibody designed to address a genetically defined form of immune dysregulation. In addition to internal efforts, Purple Biotech collaborates with academic institutions and contract research organizations to broaden its therapeutic reach and leverage specialized expertise in preclinical pharmacology and toxicology.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Purple Biotech serves a global research community through partnerships and research alliances across North America, Europe and Asia. The company maintains state-of-the-art laboratory facilities for genomics, proteomics and high-throughput screening in the Boston area, while drawing on regional collaborators to support in vivo studies and regulatory planning. These joint efforts facilitate a seamless progression of drug candidates into IND-enabling studies and eventual clinical evaluation.

Purple Biotech’s leadership team combines experience from leading biopharmaceutical companies and academic research centers. Chief Executive Officer Dr. Jane Davis previously held senior R&D roles at Genetech and Biogen, and Chief Scientific Officer Dr. Michael Chen brings over 20 years of expertise in translational genomics and drug discovery. Under their guidance, Purple Biotech continues to expand its pipeline and pursue strategic collaborations designed to bring innovative therapies to patients with significant unmet medical needs.